What You Should Know: - BioPhy, an AI drug development company, and Every Cure, a non-profit dedicated to unlocking the potential of existing drugs for new uses, today announced a strategic partnership to revolutionize drug repurposing through artificial intelligence (AI). - The partnership follows Every Cure's recent funding from the Advanced Research Projects Agency for Health (ARPA-H). A successful pilot using AI led to the identification of potential treatments for diseases like sickle
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
Deciphex & Novartis Partner on AI-Powered Pathology for Drug Discovery
What You Should Know: - Deciphex, a leading digital pathology company based in Dublin, Ireland, has announced a collaborative effort with Novartis, a prominent multinational pharmaceutical corporation. - The strategic partnership focuses on developing innovative artificial intelligence (AI) solutions aimed at revolutionizing preclinical pathology assessments within the drug discovery and development process. Optimizing Preclinical Pathology with AI The collaboration
Read More
NVIDIA Healthcare Launches Generative AI Microservices for Drug Discovery
What You Should Know: NVIDIA today launched more than two dozen new microservices that allow healthcare enterprises worldwide to take advantage of the latest advances in generative AI from anywhere and on any cloud.The new suite of NVIDIA healthcare microservices includes optimized NVIDIA NIM AI models and workflows with industry-standard APIs, or application programming interfaces, to serve as building blocks for creating and deploying cloud-native applications. They offer advanced
Read More
Absci Announces $75M Public Offering to Fuel AI Drug Creation
What You Should Know: - Absci Corporation (Nasdaq: ABSI), a company utilizing generative AI for drug discovery, announced today an initial public offering (IPO) of $75 million in common stock. - This IPO aims to support the advancement of Absci's internal drug development programs, further investment in their Integrated Drug Creation™ platform, and general corporate purposes. Offering Details Absci intends to offer $75M of common stock, with an option to sell an additional $11.25M
Read More
H1 Unveils GenosAI Pro: Supercharging Clinical Trials with Conversational AI
What You Should Know: - H1, the go-to resource for healthcare professionals, clinical trial information, and life sciences research, announced the launch of its conversational AI tool GenosAI Pro. - The conversational AI tool empowers pharmaceutical companies to streamline workflows, enhance data-driven decision-making, and optimize clinical trial processes within the Trial Landscape platform. Transforming Clinical Trial Design Building upon the success of GenosAI Lite, GenosAI Pro
Read More
Debiopharm and ThinkingNodeLife.ai Partner on AI-Driven Cancer Drug Development
What You Should Know: - Debiopharm, a leading independent biopharmaceutical company, and ThinkingNodeLife.ai (TNL), a pioneer in AI-powered drug discovery, today announced a groundbreaking partnership to propel the development of a cutting-edge cancer drug. - This strategic partnership combines Debiopharm's deep pharmaceutical expertise with TNL's revolutionary AI Digital Cells Lab platform, unlocking new frontiers in cancer treatment innovation. Unlocking the Hidden Potential of a
Read More
Amgen Builds Generative AI Models for Human Data Analysis and Drug Discovery
What You Should Know: - Amgen, a global leader in biotechnology, is embarking on a groundbreaking venture: Project Freyja. - The new initiative will harness the power of an NVIDIA DGX SuperPOD, christened after the Norse goddess of prediction, to accelerate drug discovery and development through AI-powered insights from one of the world's largest human datasets. Advance Drug Discovery Using NVIDIA DGX SuperPOD-Powered Insight Human Diversity Atlas: Freyja will map the landscape
Read More
Deloitte Unveils Atlas AI: Accelerating Drug Discovery with Generative AI and NVIDIA Power
What You Should Know: - Deloitte, a global leader in professional services, has unveiled Atlas AI, a groundbreaking addition to its Quartz AI™ suite, marking a significant leap forward in life sciences and healthcare (LSHC). - Built on the NVIDIA AI and NVIDIA Omniverse™ platforms, Atlas AI empowers scientists with novel tools to expedite drug discovery and bring life-saving treatments to market faster. Harnessing the Power of Generative AI Atlas AI boasts a unique arsenal of AI
Read More
Absci, PrecisionLife Partner to Develop AI-Enabled Drug Pipeline
What You Should Know: - Absci, a generative AI drug creation company, and PrecisionLife, a pioneer in computational biology for complex chronic diseases, have announced a powerful partnership to develop a joint portfolio of potential therapeutics. - This collaboration aims to leverage the strengths of both companies to address unmet medical needs and accelerate drug development. Combining Expertise for Faster, Precision-Driven Drug Discovery Key aspects of the partnership
Read More
Absci and AstraZeneca Sign $247M Partnership for AI-Powered Drug Discovery to Fight Cancer
What You Should Know: - Absci Corporation (ABSI), a pioneer in using generative AI to discover antibodies, and AstraZeneca, a global biopharmaceutical leader, announced a collaboration today to develop an AI-designed antibody for cancer. - This partnership combines Absci's cutting-edge Integrated Drug Creation™ platform with AstraZeneca's oncology expertise, aiming to accelerate the discovery of a potential new cancer treatment. Absci's AI Engine Takes the Lead Absci will leverage
Read More
